Drugs / KRAS-specific Autologous TCR-T cell injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06767046 | Feb 2025 → Nov 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic neoplasm | Corregene Biotechnology Co., Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRAS-specific Autologous TCR-T cell injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06767046 ↗ |
| Modality | Cell therapy | “T cell receptor-gene engineered T cells (TCR-T) therapy is a highly targeted form of cellular immunotherapy.” NCT06767046 ↗ |
| Target | KRAS | “The KRAS-specific autologous TCR-T cell injection will be used to treat these patients.” NCT06767046 ↗ |